Dishman Carbogen Amcis Posts Q3 FY26 Revenue of ₹7.20 Billion
Key highlights
- Dishman Carbogen Amcis reported Q3 FY26 net revenue of ₹7.198 billion, up 5.5% year-on-year.
- Q1 FY26 net revenue was ₹7.080 billion, up 35.2% year-on-year.
- CDMO revenue increased 45.0% year-on-year in Q1 FY26.
- Q2 FY25 revenue was ₹7.8904 billion, up 34.5% year-on-year.
powered by IRIS

Dishman Carbogen Amcis Limited reported net revenue of ₹7.198 billion for Q3 FY26, a 5.5% increase from ₹6.823 billion a year earlier, with higher revenue from its CDMO segment identified as the main driver. The disclosure matters because it provides investors with an updated view of activity in the company's core development and manufacturing business.
Know Dishman Carbogen Amcis inside out
Results, valuation, peers and who's buying, in one view.
What did Dishman Carbogen Amcis report for Q3 FY26?
Dishman Carbogen Amcis reported net revenue of ₹7.198 billion for the quarter ended December 31, 2025, compared with ₹6.823 billion in Q3 FY25. The year-on-year increase was 5.5%, according to the investor presentation submitted for analysts and investors under Regulations 30 and 51 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The company attributed the increase mainly to higher revenue from the contract development and manufacturing organisation, or CDMO, segment. The presentation does not provide a standalone profit figure, margin figure, order-book value, or segment-wise absolute revenue breakup in the supplied material. Therefore, the reported revenue movement is the clearest financial measure available from the Q3 disclosure.
Dishman Carbogen Amcis subsequently issued a presentation on its audited Q4 FY26 and full-year FY26 financial results on May 20, 2026. That filing stated that the presentation would be made to analysts and investors and hosted on the company website in line with the applicable SEBI regulations. The supplied extract does not state the company's full-year revenue or Q4 revenue figure.
How did the company's FY26 revenue trend develop?
Dishman Carbogen Amcis recorded stronger year-on-year revenue growth in the first quarter of FY26 before reporting a more moderate increase in Q3. Net revenue in Q1 FY26 was ₹7.080 billion, up 35.2% year-on-year, and the company said CDMO revenue rose 45.0% from the corresponding quarter of the previous year.
For Q3 FY26, revenue reached ₹7.198 billion, ₹0.118 billion higher than in Q1 FY26. These figures cover different reporting periods and should not be treated as a cumulative or full-year measure. Still, both quarterly updates identify CDMO activity as the key reason for the revenue increase.
The available disclosures also show a change from the earlier FY25 comparison period. In Q2 FY25, the company had reported revenue of ₹7.8904 billion, up 34.5% year-on-year, driven mainly by increased commercial sales in its CRAMS operations in Switzerland and India. The company now describes itself as a CDMO, reflecting its offering across development and commercial manufacturing services.
What business model supports Dishman Carbogen Amcis?
Dishman Carbogen Amcis is a fully integrated CDMO established in 1983, with capabilities spanning process research and development, late-stage clinical manufacturing, commercial manufacturing, and the supply of active pharmaceutical ingredients to innovator pharmaceutical companies. This operating model places its CDMO business at the centre of the revenue growth cited in the FY26 quarterly presentations.
Its product offering includes APIs, high-potency APIs, intermediates, phase-transfer catalysts, vitamin D analogues, cholesterol, lanolin-related products, and antiseptic and disinfectant formulations. The company has development and manufacturing sites in Switzerland, the UK, France, the Netherlands, India, and China.
The prior Q2 FY25 presentation also highlighted different operating conditions in its India business. DCAL India Quats and Generics revenue decreased 20.8% year-on-year in that quarter, which the company attributed primarily to a slowdown in the agrochemical sector. This illustrates that performance can differ across product lines and end markets even when overall revenue rises.
Got a follow-up? Ask IRIS
Why does the CDMO revenue increase matter to investors?
The CDMO revenue increase matters because Dishman Carbogen Amcis has explicitly identified this segment as the driver of both its Q1 FY26 and Q3 FY26 revenue growth. For investors assessing quarterly performance, the disclosures indicate that demand or commercial activity in the company's core development and manufacturing services supported reported revenue in those periods.
The company operates across several countries, including European locations, India, and China. Its Q2 FY25 update linked growth to commercial sales in Switzerland and India, while the Q3 FY26 update cited CDMO revenue without providing regional detail. The available information therefore supports an assessment of revenue direction, but not a precise estimate of contribution by geography or individual facilities.
No share-price reaction, earnings-per-share figure, debt data, guidance, or future revenue target is included in the supplied presentation extracts. Investors should therefore distinguish between the reported quarterly revenue data and any broader conclusion about profitability, cash flow, or valuation, none of which can be established from these disclosures alone.
What were the disclosure and presentation updates?
Dishman Carbogen Amcis made the Q3 FY26 presentation available under Regulations 30 and 51 of the SEBI listing regulations and said it was intended for analysts and investors. The company also said relevant presentations would be hosted on its website under Regulations 46 and 62 where applicable.
In September 2025, the company submitted a revised investor presentation after reporting inadvertent typographical or formatting errors on slides 20 and 23 of an earlier presentation dated September 4, 2025. It said the revised version incorporated the necessary corrections. This update was a presentation correction, not a stated revision of the quarterly revenue figures cited in the supplied material.
The company has also cautioned in its presentation disclaimer that the slides contain selected information about the group and do not purport to provide a comprehensive overview or all information needed to evaluate an investment. That qualification is relevant when reading quarterly presentation data alongside audited financial statements and other statutory disclosures.
Conclusion
Dishman Carbogen Amcis reported Q3 FY26 net revenue of ₹7.198 billion, up 5.5% from ₹6.823 billion in Q3 FY25, with higher CDMO revenue cited as the main reason. The result follows a Q1 FY26 update that showed 35.2% revenue growth, also supported by the CDMO segment, while the wider business continues to operate across pharmaceutical and speciality product categories in multiple countries.
Investors will next watch the detailed audited FY26 financial results and associated analyst presentation for information on annual revenue, profitability, margins, segment performance, and management commentary. The May 20, 2026 filing confirms that a Q4 FY26 and FY26 presentation was issued, but the supplied extract does not disclose those detailed financial figures.


